Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
RemeGen Co. Ltd. Class H ( (HK:9995) ) has provided an announcement.
RemeGen Co., Ltd. has released its unaudited financial data for the first quarter of 2025, prepared according to Chinese accounting principles. The report has been reviewed by the company’s audit committee but not by independent auditors, and stakeholders are advised to exercise caution when dealing with the company’s securities.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on the development and commercialization of innovative drugs, with a market presence on the Shanghai Stock Exchange and the Hong Kong Stock Exchange.
YTD Price Performance: 201.74%
Average Trading Volume: 6,991,215
Technical Sentiment Signal: Sell
Current Market Cap: HK$27.68B
See more data about 9995 stock on TipRanks’ Stock Analysis page.